Oncology

Repurposing drugs that block sodium channels may offer a novel therapy for cancer.

The FDA today approved the expanded use of a breakthrough therapy for the treatment of a rare form of cancer that attacks the immune system.

Benefits of tamoxifen varies among patients.

Cardinal Health Specialty Solutions today announced that it has signed a three-year agreement with RainTree Oncology Services to serve as its exclusive distributor for injectable, infused, oral oncolytic and supportive care specialty medications; and for Cardinal Health's VitalSourceTM to serve as its group purchasing organization for injectable and infused medications.

Vitamin D can stimulate the immune system to protect against a specific type of colorectal cancer.

Researchers discover how cancer resists BRAF+MEK inhibitors.

Eribulin evaluated for the first time as an early metastatic breast cancer treatment.

Chimeric antigen receptor may be able to treat a number of cancer types.

Pathway discovered that allows aggressive tumors to proliferate.

Exclusive interviews with keynote speaker Lunden and program chairman Patrick I. Borgen, MD, of Maimonides Medical Center in Brooklyn, NY, outline cutting edge treatments for patients.

Pharmacists can play a vital role by finding financial aid through foundations and co-pay programs.

Study finds lack of adherence to sun protection recommendations.

Discovery may provide hope for treatment of most common form of brain cancer.

Chemoradiotherapy regimen before surgery found to be effective in patients with localized rectal cancer.

Sunitinib found to provide unprecedented antitumor activity in treatment of thymic carcinoma.

Government office cuts 16 drugs amid funding problems.

Combinations of KEYTRUDA (pembrolizumab) with Alimta (pemetrexed), Cyramza (ramucirumab), or necitumumab to be explored

Study finds many patients not receiving radiation treatment.

Women who need bone-strengthening medications with an increased risk of endometrial cancer may benefit from nitrogen form of bisphosphonates.

American Cancer Society reports significant progress in death rates.

Targeted therapy found to shrink tumor growth.

Side effects found to make it harder for patients to concentrate.

Filgrastim is indicated to decrease the incidence of infection in patients with non-myeloid malignancies who also are receiving myelosuppressive anti-cancer drugs.

Hepatitis B vaccination reduces incidence of primary liver cancer by 84% later in life, study finds.

Many male patients being treated for prostate cancer undergo androgen deprivation therapy, which has been shown to have several risky side effects, including osteoporosis.

Drug currently being evaluated for treatment of hematological malignancies.

Researchers seek better targets for blocking events that lead to drug resistance.

Investigational drugs shut down critical genes and cancer cells responsible for tumor growth.